Healthcare Acquisition (AMEX:HAQ)
Historical Stock Chart
From Jun 2019 to Jun 2024
Healthcare Acquisition Corp. (AMEX:HAQ), a publicly-traded special
purpose acquisition company, announced that it has convened and then
adjourned without conducting any business, its Special Meeting of
Stockholders to vote on, among other things, the proposed merger
transaction with PharmAthene, Inc., a biodefense company developing and
commercializing medical countermeasures against biological and chemical
threats. The Special Meeting of Stockholders will reconvene at 10:00
a.m. E.T. on Friday, August 3rd at the offices
of McCarter & English, LLP, 245 Park Avenue, 27th
Floor, New York, NY.
The Special Meeting has been adjourned in order to allow time for the
solicitation of additional proxies for the proposals before the Special
Meeting.
In addition, it is anticipated that certain principal stockholders of
HAQ and of PharmAthene may participate in privately negotiated purchases
of shares of common stock of HAQ in transactions similar to those
described in the supplement to HAQ’s proxy
statement, dated August 1, 2007. However, the transactions described in
the supplement to HAQ’s proxy statement
provided for additional consideration to buyers under certain option and
assignment agreements. No such additional consideration will be paid to
the principal stockholders of HAQ and of PharmAthene in connection with
their purchases.
The record date for stockholders entitled to vote at the special meeting
remains the close of business on June 15, 2007.
Definitive proxy materials relating to the special meeting were filed
with the U.S. Securities and Exchange Commission on July 13, 2007 and
such materials were mailed to HAQ stockholders of record on or about
July 16, 2007 and supplemented on August 1, 2007. HAQ’s
stockholders are urged to read the proxy statement, as supplemented, and
other relevant materials if and as they become available, as they will
contain important information about the proposed merger and the related
proposals.
The Board of Directors of HAQ unanimously recommends that stockholders
vote “for” each of
the proposals related to the proposed merger transaction. Additional
information about the proposed merger and each of the other proposals
can be found in the definitive proxy statement.
HAQ stockholders with questions about the proposed merger or any of the
other proposals or who need assistance in voting their shares may call
the Company’s proxy solicitor, Morrow & Co.,
Inc., toll-free at (800) 607-0088.
Additional Information
HAQ AND ITS DIRECTORS AND EXECUTIVE OFFICERS AS WELL AS PHARMATHENE AND
ITS DIRECTORS AND EXECUTIVE OFFICERS MAY BE DEEMED TO BE PARTICIPANTS IN
THE SOLICIATION OF PROXIES FOR THE SPECIAL MEETING OF HAQ’S
STOCKHOLDERS TO BE HELD TO APPROVE THE PROPOSED MERGER. SECURITYHOLDERS
AND OTHER INTERESTED PERSONS ARE URGED TO READ THE DEFINITIVE PROXY
STATEMENT REGARDING THE PROPOSED MERGER FILED WITH THE SECURITIES AND
EXCHANGE COMMISSION ON JULY 13, 2007, AS IT CONTAINS IMPORTANT
INFORMATION ABOUT THE PROPOSED MERGER. STOCKHOLDERS WILL ALSO BE ABLE TO
OBTAIN A COPY OF THE DEFINITIVE PROXY STATEMENT, WITHOUT CHARGE, BY
DIRECTING A REQUEST TO HAQ AT: 2116 FINANCIAL CENTER, 666 WALNUT
STREET, DES MOINES, IOWA 50309. THE DEFINITIVE PROXY STATEMENT AND
THE FINAL PROSPECTUS AND OTHER SEC FILINGS OF HAQ CAN ALSO BE OBTAINED,
WITHOUT CHARGE, AT THE SECURITIES AND EXCHANGE COMMISSION’S
INTERNET SITE (http://www.sec.gov).
HAQ AND PHARMATHENE CLAIM THE PROTECTION OF THE SAFE HARBOR FOR “FORWARD-LOOKING
STATEMENTS” WITHIN THE MEANING OF THE PRIVATE
SECURITIES LITIGATION REFORM ACT OF 1995. FORWARD-LOOKING STATEMENTS ARE
STATEMENTS THAT ARE NOT HISTORICAL FACTS. SUCH FORWARD-LOOKING
STATEMENTS, BASED UPON THE CURRENT BELIEFS AND EXPECTATIONS OF
MANAGEMENT OF HAQ AND PHARMATHENE REGARDING, AMONG OTHER THINGS, THE
BUSINESS OF PHARMATHENE AND THE MERGER, ARE SUBJECT TO RISKS AND
UNCERTAINTIES, WHICH COULD CAUSE ACTUAL RESULTS TO DIFFER FROM THE
FORWARD-LOOKING STATEMENTS. RISKS AND UNCERTAINTIES INCLUDE RISKS
ASSOCIATED WITH THE RELIABILITY OF THE RESULTS OF THE INITIAL WORK
CONDUCTED ON VALORTIM™ RELATING TO ANIMAL
EFFICACY, HUMAN SAFETY AND LIKELIHOOD OF SUCCESSFUL DEVELOPMENT OF AN
EFFICIENT AND SCALABLE MANUFACTURING PROCESS, UNEXPECTED FUNDING DELAYS
BY NIAID, UNFORESEEN SAFETY ISSUES RESULTING FROM THE HANDLING OF
BACILLUS ANTHRACIS, UNFORESEEN SAFETY ISSUES RESULTING FROM THE
ADMINISTRATION OF VALORTIM™ (MDX-1303) IN
HUMAN SUBJECTS, UNCERTAINTIES RELATED TO PRODUCT MANUFACTURING. THERE
CAN BE NO ASSURANCE THAT SUCH DEVELOPMENT EFFORTS WILL SUCCEED OR THAT
OTHER DEVELOPED PRODUCTS WILL RECEIVE REQUIRED REGULATORY CLEARANCE OR
THAT, EVEN IF SUCH REGULATORY CLEARANCE WERE RECEIVED, SUCH PRODUCTS
WOULD ULTIMATELY ACHIEVE COMMERCIAL SUCCESS.
About Healthcare Acquisition Corp.
Des Moines-based Healthcare Acquisition Corp. was jointly formed by
healthcare investing pioneers, John Pappajohn and Derace L. Schaffer,
M.D. Healthcare Acquisition Corp. is a special purpose acquisition
company focused on the healthcare industry. The Company raised $75.2
million through an IPO in July, 2005. As of March 31, 2007, the Company
held approximately $71.4 million in trust. The Company’s
shares trade on the American Stock Exchange, under the symbol HAQ and
its warrants trade on the American Stock Exchange under the symbol
HAQ-WT.
About PharmAthene, Inc.
PharmAthene, a privately-held biodefense company, was formed in 2001 to
meet the critical needs of the United States by developing biodefense
products. PharmAthene is dedicated to the rapid development of important
and novel biotherapeutics to address biological pathogens and chemicals
that may be used as weapons of bioterror. PharmAthene’s
lead programs include Valortim™ and Protexia®.
For more information on PharmAthene, please visit www.PharmAthene.com.